Trial Search Results

Rituximab in Treating Patients With Hodgkin's Lymphoma

Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Ranjana Advani

Collaborator: Genentech, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: Rituximab

Phase:

Phase 2

Eligibility


INCLUSION CRITERIA

   - Age ‚Č• 3 years

   - Lymphocyte-predominant Hodgkin's disease (LPHD) of B-cell lineage

   - Biopsy-confirmed expression of CD20 antigen

   - At least one tumor mass measuring > 1.0 cm in largest dimension

   - No evidence of active infection

   - Subjects at high risk of Hepatitis B virus (HBV) infection should be screened prior to
   enrollment.

   - Performance status of 0 to 2

   - Absolute neutrophil count (ANC) > 1500/mL

   - Platelet count > 50,000/mL

   - Serum creatinine (Cr) < 1.5 x upper limit of normal (ULN)

   - Alkaline phosphatase < 2 x ULN, unless related to primary disease

   - Bilirubin < 2 x ULN, unless related to primary disease

   - Aspartate transaminase (AST) and alanine transaminase (ALT) < 2 x ULN, unless related
   to primary disease

   - Subjects must be able to read and sign Institutional Review Board-approved informed
   consent

EXCLUSION CRITERIA

   - Life expectancy at least 12 weeks

   - Evidence of other active malignancies other than cured carcinomas in situ of the
   cervix or basal cell carcinoma of the skin

   - Active HBV infection or hepatitis.

   - Serious non-malignant disease (eg, congestive heart failure, or active uncontrolled
   bacterial, viral, or fungal infections)

   - Concomitant or treatment within prior 4 weeks with radiotherapy or chemotherapy
   (within prior 6 weeks for nitrosourea compounds)

   - Concurrent treatment with prednisone or other systemic steroid medication

   - Treatment with any investigational drug within 30 days prior to entry into the study

   - Treatment with any investigational drug within 5 half-lives of that drug prior to
   entry into the study

   - Major surgery, other than diagnostic surgery, within 4 weeks

   - Any other conditions which, in the opinion of the investigator and/or sponsor, would
   compromise other protocol objectives

   - Female patients must be of non-childbearing potential or using adequate contraception
   with a negative pregnancy test at study entry

Ages Eligible for Study

3 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sarah Daadi
6507256456
Not Recruiting